

FUNDING ANNOUNCEMENT

Seven outstanding early-career researchers named 2024 Terry Fox New Investigators

The Terry Fox Research Institute has awarded seven future cancer research leaders with more than \$3.1M over the next three years as recipients of the Terry Fox New Investigator Awards.

Notably, policy changes in 2023 aimed at diversifying the talent pool in the NIs resulted in a significant increase in applications. This is the largest number of NIs ever funded by TFRI and correspondingly, the largest total amount awarded at one time by this competition.

We will be announcing the winners and sharing more details about these exciting new projects in the New Year. Stay tuned!

RESEARCH HIGHLIGHTS




Researchers identify drivers of childhood cancers and develop model to explore treatments

A team of TFRI-funded researchers in British Columbia verified two drivers of cancerous tumours caused by DICER1 syndrome. Their newly developed animal model will allow them to track DICER1 cancer growth and test novel therapies.



Blood test detects tumours early in families with cancer

Toronto-funded researchers have demonstrated that by analyzing patients' blood samples, they are able to detect cancer earlier in individuals with Li-Fraumeni syndrome, an inherited condition with an almost 100 percent lifetime risk of developing cancer.



uOttawa researchers find new clinical trial drug boosts cancer-fighting viruses

Terry Fox Program Project Grant team members identified a method to boost the activity of oncolytic viruses by pairing one with a drug currently in clinical trials. This presents an exciting new approach for patients resistant to virus treatment alone.



Study finds smoking causes mutations that disable the genes protecting us from cancer

Terry Fox-funded researchers based in Toronto have discovered one way smoking tobacco weakens the body's natural defences and leads to cancer, yielding important and actionable insights into cancer treatment and prevention.



New findings reveal novel biomarker can predict success of immunotherapy

TFRI-funded researchers in Montreal have identified a way to personalize cancer therapy by predicting which patients will have positive responses to immune checkpoint inhibitors – a form of immunotherapy that's shown remarkable survival increases.



Research team reveals new insights into chemotherapy resistance

TFRI-funded researchers at the University of Ottawa found that exposing cancer cells to sublethal doses of chemotherapeutics increases the resistance of cell populations to higher doses of drugs.

TFRI NEWS

Meet TFRI's newest Board members

Research training awards support next generation of cancer researchers

Announcing 2023 Terry Fox Run Challenge winners

A year in review: Read our 2022-23 Impact Report!

MOHCCN celebrates exciting milestones

MOHCCN Patient Working Group meets for first-ever learning exchange event

Community celebrates Dr. Gerry Johnston's contributions



Well-known scientist Dr. Gerry Johnston was celebrated in Halifax in November for over three decades of exceptional leadership and service to cancer research in Canada. TFRI hosted the event, along with CIHR-ICR and CCS, at the Canadian Museum of Immigration at Pier 21.

A small group gathered to thank him for his deep record of service and leadership, and vision for the Canadian cancer research landscape. His contributions to training the next generation of Canadians in cancer biology have made a demonstrable difference from coast to coast.

Dr. Johnston served TFRI in many capacities including chairing and serving on several awards' competition selection committees for many years.

Links is compiled and circulated quarterly by TFRI to highlight recently published research by our funded investigators. It is produced by TFRI staff. We hope you enjoyed reading this issue. Please send any questions or feedback to: links@tfri.ca.

Previous issues are available online in our [E-Newsletter Archive](#).

Visit www.tfri.ca to learn more about our research investment portfolio.

TFRI is either the principal or supporting funder of the research presented here. Funded investigators are invited to submit their publications to us for consideration in an upcoming issue.